Table of Contents
ISRN Immunology
Volume 2011, Article ID 530491, 5 pages
http://dx.doi.org/10.5402/2011/530491
Clinical Study

Circulating Anti-PLAC1 Antibodies during Pregnancy and in Women with Reproductive Failure: A Preliminary Analysis

1Division of Neonatology, Department of Pediatrics, University of South Florida College of Medicine, Tampa, FL 33606, USA
2Department of Obstetrics and Gynecology, University of South Florida College of Medicine, Tampa, FL 33606, USA

Received 1 September 2011; Accepted 27 September 2011

Academic Editor: E. K. Kapsogeorgou

Copyright © 2011 Anne C. Kotto-Kome et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The aims of this study were to determine the prevalence of anti-PLAC1 antibodies in normal pregnant women and in women with infertility or recurrent pregnancy loss (RPL). Secondary outcomes were the development of complications associated with anti-PLAC1 seropositivity and the rate of seroconversion during pregnancy. Sera from 103 healthy pregnant women and 45 women with unexplained infertility or RPL were analyzed by ELISA. The prevalence of anti-PLAC1 antibodies was 2% in healthy pregnant women and 4.5% in women with unexplained infertility or RPL ( 𝑃 = 0 . 3 5 5 ). There was no detectable association of seropositivity with increased risk of pregnancy complications. Finally, 2% of women seroconverted during pregnancy. The prevalence of anti-PLAC1 antibodies in women with unexplained infertility or RPL is not significantly higher than the prevalence in normal pregnant women. However, the sample size in this study was too small. The exposure to the PLAC1 antigen during pregnancy can lead to the spontaneous development of antibodies.